Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Berkshire Hathaway Inc Class B (BRK.B) vs Cytokinetics Inc (CYTK) Price & Performance

Berkshire Hathaway Inc Class BTrade
Cytokinetics IncTrade

Price performance (Past 24H)

Key statistics

Berkshire Hathaway Inc Class B vs Cytokinetics Inc — how do they compare? Berkshire Hathaway Inc Class B trades at $508.95, while Cytokinetics Inc trades at $76.34 (market cap $10.63B). The key difference: Cytokinetics Inc is trading nearer its 52-week high, Berkshire Hathaway Inc Class B nearer its low. Which is the better fit depends on your goals.

BRK.BCYTK
Sector
FinancialsTechnology
52-Week High
$529.65$87.26
52-Week Low
$465.39$34.31
Market Cap
$10.63B
Enterprise Value
$10.74B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Berkshire Hathaway Inc Class B

BRK.B trades at $529.65, up 1.73% today, with a bullish technical signal from moving averages and oscillators. The stock is near its pivot point of $530, with support at $522 and resistance at $536. Analyst consensus is positive, with 57% of 7 analysts rating it a Buy and none recommending Sell, indicating strong institutional confidence.

The outlook remains favorable given the bullish technicals and analyst support, though overbought RSI readings suggest near-term caution. Key risks include market volatility and macroeconomic pressures, but the stock's strong fundamentals and institutional backing provide a solid foundation for potential growth.

Cytokinetics Inc

CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.

The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Berkshire Hathaway Inc Class B

Berkshire Hathaway is a holding company with diverse subsidiaries, primarily in insurance through Geico and its reinsurance groups. It reinvests profits into various industries, owning Burlington Northern Santa Fe (railroad), Berkshire Hathaway Energy, and major manufacturing, service, and retail businesses like Precision Castparts and Lubrizol. The company operates in a highly decentralized manner.

Read more on BRK.B

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK